A novel cabazitaxel liposomes modified with ginsenoside Rk1 for cancer targeted therapy  

作　　者：Dandan Huang Zhongjie Tang Xiao Pu Tianqi Wang Feiyan Gao Chong Li 

机构地区：[1]Medical Research Institute,College of Pharmaceutical Sciences,Southwest University,Chongqing,China [2]Department of Pharmacy,National University of Singapore,Singapore 117545,Singapore

出　　处：《Acupuncture and Herbal Medicine》2024年第1期113-121,共9页针灸和草药（英文）

基　　金：supported by the National Natural Science Foundation of China(82373808);Chongqing Natural Science Foundation(cstc2021jcyj-bshX0125);Fundamental Research Funds for the Central Universities(SWURC2020001);the project for Chongqing University Innovation Research Group,Chongqing Education Committee(CXQT20006).

摘　　要：Objective:In this study,we aim to enhance the anti-prostate cancer efficacy of cabazitaxel(CTX)and reduce its immunosuppression and systemic toxicity by developing CTX-loaded liposomes modified with ginsenoside Rk1(Rk1/CTX-Lip).Methods:Physical and chemical properties of Rk1/CTX-Lip were investigated.We evaluated the biological functions of Rk1/CTXLip,both in vitro and in vivo.A subcutaneous prostate cancer(RM-1)-bearing mouse model was established to study the efficacy of Rk1/CTX-Lip inhibition in tumors.Simultaneously,a Candida albicans infection model was established in tumor-bearing mice to study the infection-relieving efficacy of Rk1/CTX-Lip.Finally,biocompatibility and in vivo safety of Rk1/CTX-Lip were evaluated.Results:We successfully prepared Rk1/CTX-Lip,achieving high CTX encapsulation efficiency(97.24±0.75)%and physical stability.Rk1/CTX-Lip demonstrated evasion of macrophage phagocytosis,effective tumor tissue targeting,and a significant reduction(>50%)in average tumor volume compared with Chol/CTX-Lip.Moreover,it relieved the concurrent infection burden and effectively regulated immune organs and cells,demonstrating superior biocompatibility.Conclusion:Rk1/CTX-Lip presents a promising new therapy for prostate cancer and holds potential for relieving concurrent fungal infections in cancer patients with low immunity.

关 键 词：CABAZITAXEL Fungal infection Ginsenoside Rk1 Liposome-drug delivery system Prostate cancer 

分 类 号：R285[医药卫生—中药学]